Allergan Given a $145.00 Price Target at Susquehanna (AGN)
Investment analysts at Susquehanna set a $145.00 price objective on shares of Allergan (NYSE:AGN) stock in a note issued to investors on Wednesday, Stock Ratings Network reports. Susquehanna’s target price suggests a potential upside of 19.62% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Argus raised their price target on shares of Allergan from $110.00 to $125.00 in a research note to investors on Wednesday, January 8th. They now have a “buy” rating on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Allergan from $103.00 to $122.00 in a research note to investors on Tuesday, January 7th. Finally, analysts at RBC Capital initiated coverage on shares of Allergan in a research note to investors on Tuesday, January 7th. They set an “outperform” rating and a $131.00 price target on the stock. Eight analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $114.61.
Allergan (NYSE:AGN) traded up 1.46% on Wednesday, hitting $122.995. 1,124,641 shares of the company’s stock traded hands. Allergan has a 1-year low of $81.33 and a 1-year high of $121.35. The stock has a 50-day moving average of $104.7 and a 200-day moving average of $94.04. The company has a market cap of $36.549 billion and a P/E ratio of 36.74.
Allergan (NYSE:AGN) last announced its earnings results on Tuesday, October 29th. The company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.03. The company had revenue of $1.23 billion for the quarter, compared to the consensus estimate of $1.53 billion. During the same quarter in the previous year, the company posted $1.06 earnings per share. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. On average, analysts predict that Allergan will post $4.76 earnings per share for the current fiscal year.
Allergan, Inc, is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.